Literature DB >> 28512251

Inhibition of the Cell Death Pathway in Nonalcoholic Steatohepatitis (NASH)-Related Hepatocarcinogenesis Is Associated with Histone H4 lysine 16 Deacetylation.

Aline de Conti1, Kostiantyn Dreval1, Volodymyr Tryndyak1, Orish E Orisakwe1,2, Sharon A Ross3, Frederick A Beland1, Igor P Pogribny4.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers, and its incidence is steadily increasing worldwide. Recent epidemiologic findings have suggested that the increased incidence of HCC is associated with obesity, type II diabetes mellitus, and nonalcoholic steatohepatitis (NASH); however, the mechanisms and the molecular pathogenesis of NASH-related HCC are not fully understood. To elucidate the underlying mechanisms of the development of NASH-related HCC, we investigated the hepatic transcriptomic and histone modification profiles in Stelic Animal Model mice, the first animal model of NASH-related HCC to resemble the disease pathogenesis in humans. The results demonstrate that the development of NASH-related HCC is characterized by progressive transcriptomic alterations, global loss of histone H4 lysine 20 trimethylation (H4K20me3), and global and gene-specific deacetylation of histone H4 lysine 16 (H4K16). Pathway analysis of the entire set of differentially expressed genes indicated that the inhibition of cell death pathway was the most prominent alteration, and this was facilitated by persistent gene-specific histone H4K16 deacetylation. Mechanistically, deacetylation of histone H4K16 was associated with downregulation of lysine acetyltransferase KAT8, which was driven by overexpression of its inhibitor nuclear protein 1 (Nupr1). The results of this study identified a reduction of global and gene-specific histone H4K16 acetylation as a key pathophysiologic mechanism contributing to the development of NASH-derived HCC and emphasized the importance of epigenetic alterations as diagnostic and therapeutic targets for HCC.Implications: Histone H4K16 deacetylation induces silencing of genes related to the cell death that occurred during the development of NASH-related HCC. Mol Cancer Res; 15(9); 1163-72. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28512251     DOI: 10.1158/1541-7786.MCR-17-0109

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  15 in total

1.  Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma.

Authors:  Igor P Pogribny; Kostiantyn Dreval; Iryna Kindrat; Stepan Melnyk; Leandro Jimenez; Aline de Conti; Volodymyr Tryndyak; Marta Pogribna; Juliana Festa Ortega; S Jill James; Ivan Rusyn; Frederick A Beland
Journal:  FASEB J       Date:  2018-01-03       Impact factor: 5.191

2.  Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.

Authors:  Barbara Borowa-Mazgaj; Aline de Conti; Volodymyr Tryndyak; Colleen R Steward; Leandro Jimenez; Stepan Melnyk; Mulugeta Seneshaw; Faridodin Mirshahi; Ivan Rusyn; Frederick A Beland; Arun J Sanyal; Igor P Pogribny
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

3.  Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis.

Authors:  Aline de Conti; Volodymyr Tryndyak; Renato Heidor; Leandro Jimenez; Fernando Salvador Moreno; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  J Nutr Biochem       Date:  2020-09-11       Impact factor: 6.048

4.  LncRNA ANCR promotes hepatocellular carcinoma metastasis through upregulating HNRNPA1 expression.

Authors:  Zhili Wen; Lingyan Lian; Hao Ding; Youwen Hu; Zhihua Xiao; Kai Xiong; Qian Yang
Journal:  RNA Biol       Date:  2020-01-02       Impact factor: 4.652

5.  MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis.

Authors:  Aline de Conti; Juliana Festa Ortega; Volodymyr Tryndyak; Kostiantyn Dreval; Fernando Salvador Moreno; Ivan Rusyn; Frederick A Beland; Igor P Pogribny
Journal:  Oncotarget       Date:  2017-08-01

6.  Corn dried distillers grains with solubles (cDDGS) in the diet of pigs change the expression of adipose genes that are potential therapeutic targets in metabolic and cardiovascular diseases.

Authors:  Maria Oczkowicz; Tomasz Szmatoła; Małgorzata Świątkiewicz; Klaudia Pawlina-Tyszko; Artur Gurgul; Tomasz Ząbek
Journal:  BMC Genomics       Date:  2018-12-03       Impact factor: 3.969

7.  Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis.

Authors:  Kostiantyn Dreval; Volodymyr Tryndyak; Aline de Conti; Frederick A Beland; Igor P Pogribny
Journal:  Front Genet       Date:  2019-05-29       Impact factor: 4.599

8.  Serum response factor (SRF) promotes ROS generation and hepatic stellate cell activation by epigenetically stimulating NCF1/2 transcription.

Authors:  Ming Kong; Xuyang Chen; Fangqiao Lv; Haozhen Ren; Zhiwen Fan; Hao Qin; Liming Yu; Xiaolei Shi; Yong Xu
Journal:  Redox Biol       Date:  2019-08-15       Impact factor: 11.799

Review 9.  The Role of Histone Acetylation-/Methylation-Mediated Apoptotic Gene Regulation in Hepatocellular Carcinoma.

Authors:  Pradeep Kumar Rajan; Utibe-Abasi Udoh; Juan D Sanabria; Moumita Banerjee; Gary Smith; Mathew Steven Schade; Jacqueline Sanabria; Komal Sodhi; Sandrine Pierre; Zijian Xie; Joseph I Shapiro; Juan Sanabria
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

10.  Dysregulation of intercellular signaling by MOF deletion leads to liver injury.

Authors:  Hongwei Lei; Aaron D denDekker; Guobing Li; Zhiguo Zhang; Liang Sha; Matthew A Schaller; Steven L Kunkel; Liangyou Rui; Kaixiong Tao; Yali Dou
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.